High impact, high value, evidence-based therapies for the treatment of cardiovascular diseases

Learn More

Addressing Unmet Cardiovascular Needs

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, affect large patient populations and drive a significant portion of healthcare costs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year or 31% of all global deaths according to the World Health Organization. Cardiovascular diseases are the leading cause of death in the U.S. as well, causing 774,165 deaths or over 28.5% of all deaths in 2015 according to the CDC. Despite medical advancements, there remains significant need for improvement in clinical outcomes associated with cardiovascular disease.

[   17.7M people die every year from cardiovascular diseases   ]

Product Pipeline Overview

Product pipeline targets large initial markets with significant growth opportunities in expansion future indications.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies target clear unmet needs in high risk patients

News & Events

Orchestra BioMed® to Present at Oppenheimer 29th Annual Healthcare Conference

March 13, 2019

- Presentation with live audio webcast on Tuesday, March 19, 2019 at 3:20 p.m. ET -

Webcast Link: https://www.veracast.com/webcasts/opco/healthcare2019/82115698694.cfm

New Hope, PA., March 13, 2019 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that David Hochman, Chairman and Chief Executive Officer, will present at Oppenheimer’s 29th Annual Healthcare Conference on Tuesday, March 19, 2019 at 3:20 p.m. ET in New York, NY.

Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

December 4, 2018

- Industry veteran brings over 25 years of financial and operational management experience with a proven track record of developing and implementing successful strategies to drive growth and build shareholder value -

Read All News